Ponsonnaille J, Citron B, Trolese J F, Serignat B, Gras H
Ann Cardiol Angeiol (Paris). 1987 Mar;36(3):149-53.
Betaxolol is a new cardioselective beta-blocker without any intrinsic sympathomimetic activity. A study of the cardiac electrophysiological effects of this molecule used intravenously was carried out in 20 patients. Betaxolol prolongs the sinus cycle (+ 25%, p 0.001), prolongs the sino-atrial conduction time (+ 20.1%) and atrio-hissian conduction time (+ 10.8%, p 0.001), and prolongs the refractory periods at all levels: atrial (+ 8%), nodal (+ 20.8%), right ventricular (+ 4.3%). These findings confirm the electrophysiological characteristic effects of the beta-blockers series; however, the moderate but significant increase of the refractory ventricular period, seems to provide this molecule with a certain degree of originality in this therapeutic class.
倍他洛尔是一种新型的心脏选择性β受体阻滞剂,无任何内在拟交感活性。对20例患者进行了一项关于静脉注射该分子的心脏电生理效应的研究。倍他洛尔可延长窦性周期(+25%,p<0.001),延长窦房传导时间(+20.1%)和房室希氏束传导时间(+10.8%,p<0.001),并延长各级的不应期:心房(+8%)、结区(+20.8%)、右心室(+4.3%)。这些发现证实了β受体阻滞剂系列的电生理特征性效应;然而,难治性心室期的适度但显著增加,似乎使该分子在这一治疗类别中具有一定程度的独特性。